NEW YORK, Nov. 2, 2022 /PRNewswire/ -- Collaboration for research and development is one of the key peptide therapeutics market trends that is expected to impact the industry positively in the forecast period. Companies are entering into strategic alliances to overcome technological and research challenges. For instance, AstraZeneca entered into a collaboration agreement with Bicycle Therapeutics for the development of novel peptide-based therapies using Bicycles. The pharmaceutical companies such as Novo Nordisk, Zealand Pharma, and Zydus Cadila sponsor various research programs with the Peptide Therapeutics Foundation, a not-for-profit organization focusing on the development of peptides for the treatment of various indications, which will further support the market growth in the coming years.
The peptide therapeutics market size is expected to grow by USD 23.36 billion from 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 12.52% during the forecast period, according to Technavio. The increasing prevalence of infectious diseases are driving the peptide therapeutics market growth. However, factors such as Stringent regulatory policies may challenge the market growth.
Get a comprehensive report summary that describes the market size and forecast along with research methodology. The FREE sample report is available in PDF format
By route of administration, the parenteral segment will be the largest contributor to market growth during the forecast period. Most of the major peptide drugs that are currently approved in the market are administered through the parenteral route. The popularity of parenteral RoA for peptide therapeutics is largely due to the rapid absorption of drugs and, thereby, the avoidance of drug loss through first-pass metabolism. Such factors will drive segment growth in the coming years.
Subscribe to our "Basic Plan" billed annually at USD 5000 that enables you to download 5 reports and view 100 reports per month
By geography, the market has been segmented into North America, Europe, APAC, and Rest of World (ROW). North America is going to have lucrative growth during the forecast period. About 39% of the market's overall growth is expected to originate from the region. US, Canada, and Mexico are the key markets for knee replacement in North America. Market growth in this region will be faster than the growth of the market in Rest of World (ROW).
Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a FREE PDF Sample Report
- Amgen Inc. - The unified segment focuses on discovering, developing, manufacturing, and delivering innovative human therapeutics.
- Almac Group Ltd.- The company offers automotive projector headlamps that provide ability to increase safety and functionality, but it also affords customers the opportunity to differentiate their vehicles with lighting design and create customizable driving experiences that can evoke a sense of well-being for the driver.
- AmbioPharm Inc. - The company offers automotive projector headlamps that help to make driving comfortable and safe.
- Bristol Myers Squibb Co. - The company offers automotive projector headlamps that allow the driver to travel in his vehicle with a permanent high beam without the risk of dazzling other vehicles.
This report provides a full list of key vendors, their strategies, and the latest developments. Buy Now for detailed vendor information.
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers market data for 2020, 2021, until 2025
- Market trends (drivers, opportunities, threats, challenges, investment opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Breast Cancer Therapeutics Market by Product and Geography – Forecast and Analysis 2022-2026: The breast cancer therapeutics market share is expected to increase by USD 13.85 billion from 2021 to 2026.
Gastrointestinal Stromal Tumors Therapeutics Market by Route of Administration and Geography – Forecast and Analysis 2022-2026: The gastrointestinal stromal tumors therapeutics market share is expected to increase by USD 1.08 billion from 2021 to 2026.
Peptide Therapeutics Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 12.52% |
Market growth 2022-2026 |
USD 23.36 billion |
Market structure |
Fragmented |
YoY growth (%) |
8.8 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 39% |
Key consumer countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
Almac Group Ltd., AmbioPharm Inc., Amgen Inc., AstraZeneca Plc, Bachem AG, Bristol Myers Squibb Co., Corden Pharma International GmbH, Eli Lilly and Co., Ever Pharma, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Ipsen Pharma, Lonza Group Ltd., Novartis AG, Novo Nordisk AS, PeptiDream Inc., Pfizer Inc., PolyPeptide Group, Sanofi, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Worg pharma |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of Contents:
1 Executive Summary
- 1.1 Market Overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market Definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.3 Market size 2021
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Route of Administration
- 5.1 Market segments
- Exhibit 24: Chart on Route of Administration - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Route of Administration - Market share 2021-2026 (%)
- 5.2 Comparison by Route of Administration
- Exhibit 26: Chart on Comparison by Route of Administration
- Exhibit 27: Data Table on Comparison by Route of Administration
- 5.3 Parenteral - Market size and forecast 2021-2026
- Exhibit 28: Chart on Parenteral - Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Parenteral - Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Parenteral - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Parenteral - Year-over-year growth 2021-2026 (%)
- 5.4 Oral - Market size and forecast 2021-2026
- Exhibit 32: Chart on Oral - Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Oral - Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Oral - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Oral - Year-over-year growth 2021-2026 (%)
- 5.5 Others - Market size and forecast 2021-2026
- Exhibit 36: Chart on Others - Market size and forecast 2021-2026 ($ million)
- Exhibit 37: Data Table on Others - Market size and forecast 2021-2026 ($ million)
- Exhibit 38: Chart on Others - Year-over-year growth 2021-2026 (%)
- Exhibit 39: Data Table on Others - Year-over-year growth 2021-2026 (%)
- 5.6 Market opportunity by Route of Administration
- Exhibit 40: Market opportunity by Route of Administration ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 42: Chart on Market share by geography 2021-2026 (%)
- Exhibit 43: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 44: Chart on Geographic comparison
- Exhibit 45: Data Table on Geographic comparison
- 7.3 North America - Market size and forecast 2021-2026
- Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)
- 7.4 Europe - Market size and forecast 2021-2026
- Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)
- 7.5 Asia - Market size and forecast 2021-2026
- Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- 7.7 US - Market size and forecast 2021-2026
- Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)
- 7.8 Germany - Market size and forecast 2021-2026
- Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%)
- 7.9 China - Market size and forecast 2021-2026
- Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%)
- 7.10 UK - Market size and forecast 2021-2026
- Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%)
- 7.11 Canada - Market size and forecast 2021-2026
- Exhibit 78: Chart on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 79: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 80: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 81: Data Table on Canada - Year-over-year growth 2021-2026 (%)
- 7.12 Market opportunity by geography
- Exhibit 82: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.1 Market drivers
- 8.2 Market challenges
- 8.3 Impact of drivers and challenges
- Exhibit 83: Impact of drivers and challenges in 2021 and 2026
- 8.4 Market trends
9 Vendor Landscape
- 9.1 Overview
- 9.2 Vendor landscape
- Exhibit 84: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 85: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 86: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 87: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 88: Matrix on vendor position and classification
- 10.3 Amgen Inc.
- Exhibit 89: Amgen Inc. - Overview
- Exhibit 90: Amgen Inc. - Product / Service
- Exhibit 91: Amgen Inc. - Key offerings
- 10.4 AstraZeneca Plc
- Exhibit 92: AstraZeneca Plc - Overview
- Exhibit 93: AstraZeneca Plc - Product / Service
- Exhibit 94: AstraZeneca Plc - Key news
- Exhibit 95: AstraZeneca Plc - Key offerings
- 10.5 Eli Lilly and Co.
- Exhibit 96: Eli Lilly and Co. - Overview
- Exhibit 97: Eli Lilly and Co. - Product / Service
- Exhibit 98: Eli Lilly and Co. - Key offerings
- 10.6 Ever Pharma
- Exhibit 99: Ever Pharma - Overview
- Exhibit 100: Ever Pharma - Product / Service
- Exhibit 101: Ever Pharma - Key offerings
- 10.7 GlaxoSmithKline Plc
- Exhibit 102: GlaxoSmithKline Plc - Overview
- Exhibit 103: GlaxoSmithKline Plc - Business segments
- Exhibit 104: GlaxoSmithKline Plc - Key news
- Exhibit 105: GlaxoSmithKline Plc - Key offerings
- Exhibit 106: GlaxoSmithKline Plc - Segment focus
- 10.8 Novo Nordisk AS
- Exhibit 107: Novo Nordisk AS - Overview
- Exhibit 108: Novo Nordisk AS - Business segments
- Exhibit 109: Novo Nordisk AS - Key offerings
- Exhibit 110: Novo Nordisk AS - Segment focus
- 10.9 Pfizer Inc.
- Exhibit 111: Pfizer Inc. - Overview
- Exhibit 112: Pfizer Inc. - Product / Service
- Exhibit 113: Pfizer Inc. - Key news
- Exhibit 114: Pfizer Inc. - Key offerings
- 10.10 Sanofi
- Exhibit 115: Sanofi - Overview
- Exhibit 116: Sanofi - Business segments
- Exhibit 117: Sanofi - Key news
- Exhibit 118: Sanofi - Key offerings
- Exhibit 119: Sanofi - Segment focus
- 10.11 Takeda Pharmaceutical Co. Ltd.
- Exhibit 120: Takeda Pharmaceutical Co. Ltd. - Overview
- Exhibit 121: Takeda Pharmaceutical Co. Ltd. - Product / Service
- Exhibit 122: Takeda Pharmaceutical Co. Ltd. - Key news
- Exhibit 123: Takeda Pharmaceutical Co. Ltd. - Key offerings
- 10.12 Teva Pharmaceutical Industries Ltd.
- Exhibit 124: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 125: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 126: Teva Pharmaceutical Industries Ltd. - Key news
- Exhibit 127: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 128: Teva Pharmaceutical Industries Ltd. - Segment focus
11 Appendix
- 11.1 Scope of the report
- 11.2 Inclusions and exclusions checklist
- Exhibit 129: Inclusions checklist
- Exhibit 130: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 131: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 132: Research methodology
- Exhibit 133: Validation techniques employed for market sizing
- Exhibit 134: Information sources
- 11.5 List of abbreviations
- Exhibit 135: List of abbreviations
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article